Thermo Fisher Scientific Inc. (NYSE: TMO), Waltham, MA, has agreed to acquire Brammer Bio for $1.7 billion. The acquisition would expand the lab-equipment company’s presence in the field of gene therapy.
Brammer Bio, owned by private-equity firm Ampersand Capital Partners, provides pharmaceutical companies developing gene therapies and gene-modified cell therapies with outsourced research and drug making services.
Brammer Bio was formed in 2016 through the merger of Brammer Biopharmaceuticals and Florida Biologix.
Related Posts
-
Columbia Pipe is an independent distributor specializing in PVF, commercial mechanical, commercial plumbing, industrial, valve…
-
DGI Supply has hired the Production Tool & Supply employees and will continue to operate…
-
Emerson says acquisition will complement the company’s portfolio and “help customers in discrete and hybrid…
